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Summary
Background: High inter-individual variability in therapeutic response to drugs used 
in the management of Inflammatory Bowel Disease (IBD) leads to high morbidity and 
high costs. Genetic variants predictive of thiopurine-induced myelosuppression, thi-
opurine-induced pancreatitis and immunogenicity of Tumour Necrosis Factor alpha 
(TNFα) antagonists have been identified, but uptake of pre-treatment pharmacoge-
netic testing into clinical guidelines has been slow.
Aim: To explore the efficacy of a pharmacogenetic passport for IBD that includes 
multiple pharmacogenetic predictors of response.
Methods: Patients with IBD exposed to thiopurines and/or TNFα antagonists were 
retrospectively evaluated for the presence of thiopurine toxicity and/or immuno-
genicity of TNFα antagonists. All patients were genotyped using both whole-exome 
sequencing and the Illumina Global Screening Array. An in-house-developed compu-
tational pipeline translated genetic data into an IBD pharmacogenetic passport that 
predicted risks for thiopurine toxicity and immunogenicity of TNFα antagonists per 
patient. Using pharmacogenetic-guided treatment guidelines, we calculated clinical 
efficacy estimates for pharmacogenetic testing for IBD.
Results: Among 710 patients with IBD exposed to thiopurines and/or TNFα an-
tagonists, 150 adverse drug responses occurred and our pharmacogenetic passport 
would have predicted 54 (36%) of these. Using a pharmacogenetic passport for IBD 
that includes genetic variants predictive of thiopurine-induced myelosuppression, 
thiopurine-induced pancreatitis, and immunogenicity of TNFα antagonists, 24 pa-
tients need to be genotyped to prevent one of these adverse drug responses.
Conclusions: This study highlights the clinical efficacy of a pharmacogenetic pass-
port for IBD. Implementation of such a pharmacogenetic passport into clinical man-
agement of IBD may contribute to a reduction in adverse drug responses.
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1  | INTRODUC TION
Inflammatory Bowel Disease (IBD) is a chronic relapsing inflam-
matory disease of the gastrointestinal tract primarily consisting of 
Crohn's disease (CD) and ulcerative colitis (UC). Medical manage-
ment of IBD aims for lasting disease remission to prevent com-
plications and disease progression.1,2 While both conventional 
immunosuppressive agents and novel biological agents are effective 
for IBD treatment, inter-individual variability in therapy response is 
high, both with respect to efficacy and toxicity.3 This inter-individual 
variability contributes to high rates of therapeutic failure in IBD, and 
better patient stratification is therefore needed to maximise patient 
benefit and minimise the harm caused by adverse events.
Thiopurines (mercaptopurine and its prodrug azathioprine) are 
conventional immunomodulators commonly used to maintain dis-
ease remission in patients with IBD. However, the use of thiopurines 
is limited by frequently occurring adverse drug reactions, includ-
ing thiopurine-induced myelosuppression and thiopurine-induced 
pancreatitis, from hereon referred to as myelosuppression and 
pancreatitis respectively. Myelosuppression is a dose-dependent 
adverse reaction with a cumulative incidence of 7%. Most patients 
with myelosuppression are asymptomatic, but serious opportunis-
tic infections require hospitalisation in 30% of the patients, with 
an estimated mortality of 1%.4 Genetic variants in the thiopurine 
S-methyltransferase (TPMT) and nudix hydrolase 15 (NUDT15) 
genes, which both encode enzymes involved in thiopurine metab-
olism, are associated with an increased risk of myelosuppression.5,6 
Pancreatitis occurs in about 4% of thiopurine-exposed patients,7 and 
the pathogenesis of this potentially life-threatening, idiosyncratic 
adverse reaction remains poorly understood. The HLA-DQA1-HLA-
DRB1 haplotype has been identified as a genetic determinant for 
pancreatitis.8,9
Tumour Necrosis Factor alpha (TNFα) antagonists, mainly inflix-
imab and adalimumab, are the most commonly prescribed biologi-
cals in the management of IBD.10 Biological therapy has transformed 
the management of IBD and has become the largest contribution to 
IBD healthcare expenditure.11 Up to 65% of patients treated with 
infliximab and 38% of patients treated with adalimumab will lose re-
sponse due to formation of anti-drug antibodies, a process referred 
to as immunogenicity.12 Concomitant use of conventional immuno-
modulators can reduce immunogenicity. Recently, the HLA-DQA1*05 
haplotype was identified as a genetic determinant of immunogenic-
ity of TNFα antagonists.13
Given the increasing number of available therapeutic options, 
and the costs associated with them, there is a clear need for bio-
markers predicting individual response to therapy in order to make 
personalised medicine decisions. We explore pre-treatment pharma-
cogenetic testing, which has the potential to maximise patient ben-
efit by optimising drug selection and dose, and minimise the harm 
caused by drug toxicity. In addition, avoiding (expensive) drugs that 
are either ineffective or harmful by optimising the use of relatively 
cheap conventional drugs and achieving optimal dosing as early as 
possible, will lead to a significant reduction in costs.
Despite this compelling rationale for pre-treatment pharmacoge-
netic testing in the context of IBD management, and the falling costs 
of genetic tests, the implementation of pharmacogenetic-based 
guidelines in the clinic has been challenging. In this study, we show 
that a pharmacogenetic profile or ‘passport’ devised from genetic 
data, would provide IBD patients with personalised therapeutic rec-
ommendations based on their genotypes, leading to a potentially 
significant reduction in costs and therapeutic failure rates in the 
management of IBD.
2  | METHODS
All patients with IBD treated at the University Medical Center 
Groningen, a large IBD-specialised tertiary hospital, are prospec-
tively followed using an electronic IBD-specific electronic health 
record. Patients with IBD treated with thiopurines (azathioprine 
and/or mercaptopurine) and/or TNFα antagonists (infliximab and/
or adalimumab) between January 1981 and December 2018 were 
included in this study. Patients were genotyped and their clinical 
data were collected. Each patient had been diagnosed with IBD by 
their gastroenterologist using endoscopic data, histological data, ra-
diological data or a combination of these. During the study period, 
pharmacogenetic testing was not included as routine clinical prac-
tice. All patients provided informed written consent, and the study 
was approved by the medical ethical board of the University Medical 
Center Groningen (PSI-UMCG [IRB no 08/279]).
2.1 | Adjudication of patients
Each patient exposed to thiopurine therapy was adjudicated as either 
an affected case or an unaffected control for myelosuppression and 
pancreatitis. Case and control adjudication criteria are identical to cri-
teria used in previous IBD pharmacogenetic studies 5,8 and are avail-
able in the Supplementary Data. All cases were adjudicated by IBD 
experts using a modified version of the validated Liverpool Adverse 
Drug Reaction Causality Assessment Tool and assigned a causality 
category.14 Probable myelosuppression cases needed to have dem-
onstrated a fall in white cell count to ≤2.5 × 109/L and/or a reduction 
in neutrophil count to ≤1.0 × 109/L with a clear temporal relationship 
with thiopurine exposure and without confounding risk factors. In 
addition, definite myelosuppression cases also developed a second 
episode of myelosuppression upon thiopurine re-challenge. For pos-
sible myelosuppression cases, confounding causes for the myelosup-
pression and/or missing data were allowed if the expert opinion still 
implicated thiopurines as the most likely cause. Probable pancreatitis 
cases needed to have developed an episode of severe abdominal pain 
with serum pancreatic enzymes (amylase/lipase) over two times the 
upper limit of normal within 3 months of starting thiopurine therapy 
and without confounding causes for pancreatitis. In addition, definite 
pancreatitis cases also had to have developed a second episode of 
pancreatitis upon thiopurine re-challenge. For possible pancreatitis 
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cases, confounding causes for the pancreatitis and/or missing data 
were allowed if the expert opinion still implicated thiopurines as the 
most likely cause. In addition to previously used pancreatitis criteria, 
a fourth pancreatitis causality category was added: suspected pan-
creatitis cases who developed severe abdominal pain matching pain 
associated with pancreatitis within 3 months of starting thiopurine 
therapy, with two independent physicians suspecting pancreatitis, 
but without available blood amylase or lipase measurements.
Thiopurine-tolerant controls for both myelosuppression and 
pancreatitis needed to have been exposed to thiopurines for at 
least 8 weeks without the development of myelosuppression or 
pancreatitis. All thiopurine-tolerant controls, definite and probable 
myelosuppression cases and all pancreatitis cases were included in 
subsequent analyses.
Each patient exposed to TNFα antagonist therapy was adju-
dicated as either an immunogenicity case or unaffected control. 
Patients with an anti-drug antibody titres >12 arbitrary units per mil-
lilitre (AU/mL), demanding drug withdrawal or start of concomitant 
immunomodulator therapy, were classified as immunogenicity cases. 
All other patients exposed to TNFα antagonists for at least 52 weeks 
with no signs of treatment failure to latest follow-up or to time of 
drug withdrawal, or patients with an anti-drug antibody concentra-
tion <12 AU/mL, were adjudicated as controls.
Infliximab and adalimumab antibody titres were obtained using 
drug-tolerant assays developed by Sanquin Research (Sanquin, 
Amsterdam, the Netherlands). ELISA was used to detect drug levels, 
while a radio-immuno assay was used to detect anti-drug antibodies. 
Radio-immuno assay test results were converted into arbitrary units 
per millilitre by comparison with dilutions of a reference serum. The 
cut-off level for a positive signal was set at 12 AU/mL (mean + 3 stan-
dard deviations) of the pre-treatment values. Details of these assays, 
and comparisons to other assays have been published before.15-17
We reason that all patients exposed to either thiopurine or TNFα 
antagonist therapy in our cohort are representative of future candi-
dates for these therapies, and thus for pre-treatment pharmacoge-
netic screening.
2.2 | Genotype data
All patients were genotyped using both whole-exome sequencing 
data (Illumina Hiseq 2500, Illumina) and a genome-wide genotyp-
ing array (Infinium Global Screening Array, Illumina). After quality 
control,18 alignment to the b37 human reference genome was per-
formed. In total, 86.06 million high-quality reads were generated per 
sample. On average, 98.85% of these reads aligned to the human 
genome (hg19) per sample, resulting in a >30X read depth for 81% 
of the whole exome. Genetic array data were combined with whole-
exome sequencing data using PLINK v1.9.19 To account for popu-
lation stratification, principal component analyses were performed 
using Eigenstrat v7.2.1 with 1000 Genomes Project data as refer-
ence data.20,21 Only data from patients clustering with individuals 
of non-Finnish European descent were included in subsequent 
pharmacogenetic analyses. After extensive quality control, geno-
type data were phased with the Eagle2 algorithm v2.4.22
Based on whole-exome sequencing data, six TPMT star alleles 
were identified, which together account for > 90% of the variation in 
TPMT enzyme function in Europeans: TPMT*2, TPMT*3A, TPMT*3B, 
TPMT*3C, TPMT*9 and TPMT*12. NUDT15 genetic variants are rare 
in European populations. We could identify NUDT15*3, NUDT15*6 
and NUDT15*9, which are the most common NUDT15 variant hap-
lotypes in Europeans.23 Genetic variation at HLA-DQA1*02:01-
HLA-DRB1*07:01 (rs2647087) and HLA-DQA1*05 (rs2097432) was 
defined using directly genotyped array data.
2.3 | Pharmacogenetic passport
For each patient, genetic variation at TPMT, NUDT15, HLA-
DQA1*02:01-HLA-DRB1*07:01 and HLA-DQA1*05 were translated 
into a pharmacogenetic passport using an in-house–developed com-
putational pipeline (Figure S2).
2.3.1 | Step 1
Combinations of genetic variants in TPMT or NUDT15, respectively, 
are referred to as haplotypes. The combinations of two haplotypes 
(one from each chromosome) were translated into star (*) allele diplo-
types provided by the Clinical Pharmacogenetics Implementation 
Consortium (CPIC) and the Pharmacogenomics Knowledgebase. 
TMPT*1 and NUDT15*1 were defined as reference.23,24
2.3.2 | Step 2
Star allele diplotype assignments were then used to link geno-
types with phenotypic function (ie enzyme metabolising activity) 
according to the CPIC. Patients carrying one deleterious haplo-
type (ie other than the reference haplotype) in TPMT or NUDT15 
are intermediate thiopurine metabolisers. Patient carrying two 
deleterious haplotypes (eg TPMT*2/TPMT*3A) are poor thiopurine 
metabolisers.
2.3.3 | Step 3
In this step, phenotypic function of TPMT and NUDT15 and HLA ge-
netic variation were translated into a genetic risk of drug-related 
effects.
Step 3a. Enzyme metabolising activity for TPMT and NUDT15 
was translated into a predicted risk of myelosuppression. 
Intermediate metabolisers are at intermediate risk of myelosuppres-
sion, while poor metabolisers are at high risk of myelosuppression.
Step 3b. Patients homozygous at HLA-DQA1*02:01-HLA-
DRB1*07:01 were referred to as patients at high risk of pancreatitis. In 
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this study, patients heterozygous at HLA-DQA1*02:01-HLA-DRB1*07:01 
and homozygous reference haplotype carriers were referred to as 
having a normal risk of pancreatitis.
Step 3c. Patients carrying at least one HLA-DQA1*05 risk al-
lele (ie heterozygous or homozygous) were referred to as patients 
at high risk of immunogenicity. In this study, homozygous refer-
ence haplotype carriers were referred to as having a normal risk of 
immunogenicity.
2.3.4 | Step 4
In this step, genetic risks were translated into therapeutic recom-
mendations. Therapeutic recommendations regarding TPMT and 
NUDT15 genetic variation are in line with CPIC guidelines.23 It re-
mains poorly understood how genetic variation in HLA-DQA1*02:01-
HLA-DRB1*07:01 and the HLA-DQA1*05 risk allele predisposes to 
pancreatitis or immunogenicity, but our recommendations are in line 
with previously proposed strategies.8,9,13
Step 4a. Patients at intermediate risk of myelosuppression should 
receive a reduced starting dose (30%-80% of target dose). For pa-
tients at high risk of myelosuppression, alternative treatment should 
be considered. For patients at normal risk of myelosuppression, 
starting dose does not need to be altered.
Step 4b. For patients at high risk of pancreatitis, an alternative 
treatment should be considered. We do not propose drug avoidance 
in patients heterozygous at HLA-DQA1*02:01-HLA-DRB1*07:01 (2.5-
fold increased risk of pancreatitis) because the high variant carrier 
frequency would mean drug avoidance in over one third of patients 
tested. For patients at normal risk of pancreatitis, starting doses do 
not need to be altered.
Step 4c. Concomitant immunomodulator therapy to prevent 
antibody development is proposed for patients at high genetic risk 
of immunogenicity. Patients at normal risk of immunogenicity, in-
tolerant to immunomodulators or patients who are at high risk of 
opportunistic infections might be treated with TNFα antagonist 
monotherapy.
2.3.5 | Step 5
In this step, our computational pipeline combined all of the above 
data into one ‘pharmacogenetic passport’ per patient. This pharma-
cogenetic passport may be used to aid therapeutic decisions.
2.4 | Case-control analyses
Clinical data were compared between cases and exposed controls 
for myelosuppression, pancreatitis and immunogenicity respec-
tively. Continuous data were described using medians and interquar-
tile ranges, and compared using the Mann-Whitney test. Categorical 
data were described as number and percentage, and compared 
using the Chi-square test or Fisher exact test. Weight-adjusted 
thiopurine dose (milligrams per kilograms) was calculated using the 
following formulas for mercaptopurine (mercaptopurine dose in mil-
ligrams × 2.08/weight in kilograms) and azathioprine (azathioprine 
dose in milligrams/weight in kilograms). The association of TPMT 
and/or NUDT15 genetic variation and weight-adjusted thiopurine 
dose with myelosuppression and the association of HLA-DQA1*05 
and use of combination therapy with immunogenicity were assessed 
using multivariable regression analyses. No genome-wide associa-
tion study was performed because identifying novel pharmacoge-
netic interactions was not an aim of this study.
2.5 | Clinical efficacy estimates
Predicted clinical efficacy estimates (sensitivity, specificity, nega-
tive predictive value and positive predictive value) and numbers 
needed to genotype, numbers needed to treat and numbers 
needed to harm were calculated using previously published meth-
ods.5,25,26 These estimates assumed drug-response incidence 
estimates from literature,4,7 the above-mentioned pharmaco-
genetic-based treatment strategies, genotype frequencies from 
our nation-wide Dutch IBD cohort and the odds ratio (OR) of the 
genotype-phenotype association from our present study (Table 
S1A-H).
We first calculated estimates for each pharmacogenetic pre-
dictor separately. These were then incorporated into clinical effi-
cacy estimates for a combined IBD pharmacogenetic passport. The 
number needed to genotype, number needed to treat and number 
needed to harm to prevent one case (ie of either thiopurine toxicity 
or immunogenicity of TNFα antagonists) were calculated for a sce-
nario in which an IBD pharmacogenetic genetic passport was estab-
lished prior to start of either thiopurine or TNFα antagonist therapy. 
Using the retrospective treatment-response data from our entire co-
hort of patients with IBD, we then show the potential consequences 
of our proposed pharmacogenetic-based treatment strategies. All 
statistical calculations were performed using R 3.5.1 (R Foundations 
for Statistical Computing, Vienna, Austria).
3  | RESULTS
We identified 710 patients with IBD who were exposed to thiopu-
rines and/or TNFα antagonists. Of these patients, 695 (98%) were 
exposed to thiopurines (azathioprine 586 [84%]; mercaptopurine 
109 [16%]) and 376 (53%) were exposed to TNFα antagonist therapy 
(infliximab 284 [76%]; adalimumab 92 [24%]) (Table 1).
3.1 | Case-control analyses
We first performed case-control analyses for each pharmacoge-
netic predictor separately (ie for myelosuppression, pancreatitis or 
     |  1109BANGMA et Al.






















(n = 555) P-values
Gender, No. (%)
Female 409 (59%) 19 (66%) 272 (58%) 0.54 27 (71%) 326 (59%) 0.19
Male 286 (41%) 10 (34%) 198 (42%) 11 (29%) 229 (41%)
Age, median (IQR), 
y
47 (23) 44 (31) 47 (24) 0.72 43 (23) 46 (24) 0.31
Type of IBD diagnosis,  
No. (%)
Crohn's disease 404 (58%) 19 (66%) 273 (58%) 0.32 29 (76%) 320 (58%) 0.07
Ulcerative colitis 267 (38%) 8 (28%) 182 (39%) 8 (21%) 218 (39%)
IBD unclassified 24 (3%) 2 (7%) 15 (3%) 1 (3%) 17 (3%)
Type of thiopurine,  
No. (%)
Azathioprine 586 (84%) 22 (76%) 408 (87%) 0.17 32 (84%) 472 (85%) 1 








680 (98%) 24 (83%) 466 (99%) 7.88E-05a  38 (100%) 544 (98%) 0.80
Reference/
variant
13 (2%) 4 (14%) 4 (1%) 0 (0%) 11 (2%)




628 (90%) 23 (79%) 434 (92%) 0.065a  34 (89%) 509 (92%) 0.86
Reference/
variant




617 (89%) 18 (65%) 432 (92%) 4.55E-05b  34 (89%) 500 (90%) 1
Intermediate 
metaboliser
76 (11%) 10 (32%) 38 (8%) 4 (11%) 55 (10%)




416 (60%) 21 (71%) 276 (59%) 0.42 17 (45%) 334 (60%) 0.14
Reference/
variant
284 (41%) 8 (29%) 172 (37%) 19 (50%) 199 (36%)
Variant/variant 31 (4%) 0 (0%) 22 (5%) 2 (5%) 22 (5%)
Abbreviations: HLA, human leukocyte antigen; IBD, inflammatory bowel disease; IQR, inter-quartile range; No., number; NUDT15, nudix hydrolase 
15; SD, standard deviation; TPMT, thiopurine S-methyltransferase.
aP-values from multivariate logistic regression analyses including TPMT variant status, NUDT15 variant status and weight-adjusted thiopurine dose. 
bP-values from multivariate logistic regression analyses including thiopurine metabolism and weight-adjusted thiopurine dose. NUDT15 heterozygotes 
are pooled with NUDT15 homozygotes in multivariate logistic regression analyses. 
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immunogenicity). ORs from these pharmacogenetic case-control 
analyses were used as input for clinical efficacy calculations.
3.1.1 | Thiopurine-induced myelosuppression
Of the 695 patients exposed to thiopurines, we identified 29 (4.2%) 
cases and 470 (68%) controls for myelosuppression. The remaining 
196 (28%) patients did not meet our stringent case/control adjudi-
cation criteria and were excluded. Myelosuppression cases received 
a higher weight-adjusted thiopurine dose compared with controls 
(2.17 mg/kg vs 1.85 mg/kg; P = 0.01). There were no differences 
between cases and controls when comparing gender, age, IBD di-
agnosis or type of thiopurine used. Univariate analysis revealed 
that carriage of any variant in TPMT (OR 3.13 [95% CI 1.11-7.80]; 
P = 0.02) or NUDT15 (OR 24.3 [95% CI 6.06-104]; P = 5.67E-6) was 
associated with myelosuppression. Multivariable regression analy-
ses revealed that carriage of any variant in NUDT15 (OR 20.2 [95% 
CI 4.4-94.4]; P = 7.88E-05) and weight-adjusted thiopurine dose (OR 
2.69 [95% CI 1.39-5.26]; P = 3.41E-03) were independently associ-
ated with myelosuppression (Table 1). The association of TPMT with 
myelosuppression failed to reach independent statistical signifi-
cance using multivariable regression (OR 2.86 [95% CI 0.84-8.17]; 
P = 0.065).
3.1.2 | Thiopurine-induced pancreatitis
Of 695 patients exposed to thiopurines, we identified 38 (5.5%) 
cases and 555 (80%) controls for pancreatitis. The remaining 102 
(15%) patients did not meet stringent case/control adjudication cri-
teria and were excluded. There were no differences between cases 
and controls in gender, age, IBD diagnosis, type of thiopurine used 
or weight-adjusted dose. Carriage of the HLA-DQA1-HLA-DRB1 risk 
haplotype was not significantly associated with the risk of pancrea-
titis when using a dominant genetic model (OR 1.87 [95% CI 0.97-
3.66]; P = 0.064) or when using an additive genetic model (P = 0.14) 
(Table 1).
3.1.3 | Immunogenicity of TNFα antagonists
Of 376 patients exposed to TNFα antagonist therapy, we iden-
tified 85 (23%) cases and 194 (52%) controls for immunogenic-
ity. The remaining 97 (26%) patients did not meet our stringent 
case/control adjudication criteria and were excluded. There were 
no differences between cases and controls when comparing 
gender and type of drug. Immunogenicity cases less frequently 
received concomitant immunomodulator therapy (32% vs 54%; 
P = 1.2E-4), used TNFα antagonist therapy for a shorter period of 
time (57 weeks vs 244 weeks; P = 2.44E-14), were of higher age 
(46 years old vs 42 years old, P = 0.03) and were less frequently di-
agnosed with CD (69% vs 85%, P = 0.01), compared with controls. 
Multivariable regression analysis revealed that the use of combi-
nation therapy (OR = 0.34 [95% CI 0.19-0.60], P = 2.33E-4) and 
CD (OR = 0.38 [95% CI 0.20-0.72], P = 3.26E-3) was significantly 
associated with a decreased risk of immunogenicity, while car-
riage of the HLA-DQA1*05 haplotype increased the risk. However, 
this genetic association failed to reach statistical significance in 
our multivariate model (OR = 1.65 [95% CI 0.95-2.85], P = 0.075) 
(Table 2).
3.2 | Clinical efficacy estimates
We next assessed the clinical efficacy of pharmacogenetic testing 
for three applications: (a) to predict thiopurine toxicity (ie myelosup-
pression and pancreatitis) prior to starting thiopurine treatment, (b) 
to predict immunogenicity prior to starting TNFα antagonist therapy 
and (c) to predict both thiopurine toxicity and immunogenicity of 
TNFα antagonists prior to starting either thiopurine or TNFα antago-
nist therapy (ie an IBD pharmacogenetic passport).
3.2.1 | Thiopurine toxicity
Of 695 patients exposed to thiopurines, 590 (85%) were at low ge-
netic risk of thiopurine toxicity, 72 (10%) were at intermediate risk 
of thiopurine toxicity (ie intermediate thiopurine metabolisers), and 
33 (5%) were at high genetic risk of thiopurine toxicity (2 [0.3%] 
poor thiopurine metaboliser and 31 [5%] HLA-DQA1-HLA-DRB1 
homozygotes). Four patients (0.6%) were both homozygous at the 
HLA-DQA1-HLA-DRB1 haplotype and intermediate thiopurine me-
tabolisers and they were thus classified as being at high genetic risk 
of thiopurine toxicity. Among patients at intermediate risk of thio-
purine toxicity for whom dose reduction would be recommended, 
we identified 11 (15%) patients who developed myelosuppression 
and 34 (47%) patients with uncomplicated sustained thiopurine use. 
Among patients at high genetic risk of thiopurine toxicity for whom 
drug avoidance would be recommended, we identified 3 (9%) pa-
tients who developed either myelosuppression or pancreatitis and 
21 (64%) patients with uncomplicated sustained thiopurine use 
(Figure 1). Again, a number of patients did not meet case/control 
criteria.
We calculated a number needed to genotype of 39, a number 
needed to treat of 7 and a number needed to harm of 5 to pre-
vent one case of thiopurine toxicity. This means that for every 39 
patients genotyped prior to starting thiopurine therapy, 7 will test 
positive for a predictive variant of thiopurine toxicity and 2 of them 
would have developed thiopurine toxicity without pharmacogenet-
ic-guided therapy. However, if these seven patients had received 
dose reduction or drug avoidance, depending on their predicted 
genetic risk, one case of thiopurine toxicity would have been pre-
vented. This assumes an overall risk of 7% for myelosuppression 4 
and 4% for pancreatitis,7 an incidence of poor thiopurine metabo-
lisers of 0.27% (nation-wide Dutch IBD cohort) and an incidence of 
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6.7% for HLA-DQA1-HLA-DRB1 homozygotes (nation-wide Dutch 
IBD cohort) (Table S1A-E).
3.2.2 | Immunogenicity of TNFα antagonists
Among 376 patients exposed to TNFα antagonist therapy, 149 (40%) 
patients were genetically at risk of immunogenicity. Among these 
149 patients, 40 (27%) developed immunogenicity, while 71 (48%) 
did not (Figure 1). Fifteen of 40 (38%) of these patients received con-
comitant immunomodulator therapy, which was taken into account 
in subsequent clinical efficacy calculations. Again, a number of pa-
tients did not meet case/control criteria.
We calculated a number needed to genotype of 32, a number 
needed to treat of 13 and a number needed to harm of 8 to prevent 
one case of immunogenicity. This means that for every 32 patients 
genotyped prior to starting TNFα antagonist therapy, 13 will test 
positive for the HLA-DQA1*05 haplotype and 5 would have devel-
oped immunogenicity without pharmacogenetic-guided combina-
tion therapy. However, if these patients had received concomitant 
immunomodulator therapy, one case of immunogenicity would have 
been prevented. This assumes an overall risk of immunogenicity of 
30% (this cohort), an HLA-DQA1*05 variant carrier frequency of 39% 
(nation-wide Dutch IBD cohort) and subsequent prescription of a 
concomitant immunomodulator therapy for patients genetically at 
risk (Table S1E-H).
3.2.3 | IBD pharmacogenetic passport
To explore the potential benefits of an IBD pharmacogenetic pass-
port, we combined clinical efficacy estimates for preventing thiopu-
rine toxicity and immunogenicity of TNFα antagonists into an overall 
predicted efficacy. In our total cohort of 710 IBD patients, 150 ad-
verse drug responses occurred (ie either thiopurine toxicity or immu-
nogenicity of TNFα antagonists). An IBD pharmacogenetic passport 
would have predicted 54 (36%) of these adverse drug responses, 
while 96 (64%) cases would not have been predicted (Figure 1).
We calculated a number needed to genotype of 24, a number 
needed to treat of 9 and a number needed to harm of 6 to prevent 
one adverse drug response (ie myelosuppression, pancreatitis or im-
munogenicity). This means that, for every 24 candidates for either 
thiopurine or TNFα antagonist therapy who were genotyped prior 
to starting treatment, nine patients would test positive for a pre-
dictive variant and three of them would have developed an adverse 
drug response without pharmacogenetic-guided alternative therapy. 
TA B L E  2   Patient characteristics of patients with IBD exposed to TNFα antagonists. P-values refer to comparisons between cases and 
controls
Characteristic
Patients exposed to TNFα 
antagonists (n = 376)
Immunogenicity of TNFα 
antagonists cases (n = 85)
Immunogenicity of TNFα 




Female 246 (65%) 59 (69%) 117 (60%) 0.19
Male 130 (35%) 26 (31%) 77 (40%)
Age, median (IQR), y 47 (21) 46 (27) 42 (21) 0.03
Type of IBD diagnosis, No. (%)
Crohn's disease 278 (74%) 59 (69%) 164 (85%) 0.01
Ulcerative colitis 85 (23%) 23 (27%) 25 (13%)
IBD-unclassified 13 (3%) 3 (4%) 5 (3%)
Type of TNFα antagonist, No (%)
Infliximab 284 (76%) 63 (74%) 140 (72%) 0.10
Adalimumab 92 (24%) 22 (26%) 54 (28%)
Concomitant immunomodulator, No. (%)
No 198 (53%) 59 (69%) 88 (45%) 3.5E-4
Yes 178 (47%) 26 (31%) 106 (55%)
Duration of use, median (IQR), w 206 (314) 18 (161) 200 (348) 6.84E-7
HLA-DQA1*05 haplotype
Reference/reference 227 (60%) 45 (53%) 123 (63%) 0.075a 
Reference/variant 125 (33%) 33 (39%) 60 (31%)
Variant/variant 24 (6%) 7 (8%) 11 (6%)
Abbreviations: HLA, human leukocyte antigen; IBD, inflammatory bowel disease; IQR, inter-quartile range; No., number.
aP-value from multivariate logistic regression analysis including type of IBD diagnosis, age, concomitant immunomodulator use and HLA-DQA1*05 
variant status, using a dominant genetic model. 
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F I G U R E  1   Flowchart representing current therapeutic outcomes (past) and proposed pharmacogenetic-guided treatment strategies 
(future). Patients defined as candidates for therapy in this figure were exposed to either thiopurines or TNFα antagonists and are 
hypothesised to be representative of future candidates. Toxicity refers to either thiopurine-induced myelosuppression or thiopurine-induced 
pancreatitis. Antibodies refers to the formation of anti-drug antibodies to TNFα antagonists, a process referred to as immunogenicity. 
Patients in red boxes would receive alternative treatment strategies based on pharmacogenetic testing. IBD: inflammatory bowel disease; 
TNFα: Tumour Necrosis Factor alpha
Candidate for thiopurine therapy Candidate for TNFα-antagonist therapy
695 (100%) 376 (100%) 
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However, if a pharmacogenetic-guided alternative treatment strat-
egy had been applied, one adverse drug response would have been 
prevented. This calculation makes the same assumptions for sepa-
rate clinical efficacy estimates that we used above, and a frequency 
of thiopurine use of 98% relative to a frequency of TNFα antagonist 
use of 53% based on this cohort (Supplementary Data: IBD pharma-
cogenetic passport).
4  | DISCUSSION
This real-world IBD cohort provides clinical efficacy estimates for 
the implementation of an IBD pharmacogenetic passport includ-
ing genetic variants predictive of both thiopurine toxicity and im-
munogenicity of TNFα antagonists. If such an IBD pharmacogenetic 
passport was incorporated into clinical guidelines, better patient 
stratification would lead to a significant reduction in potentially life-
threatening thiopurine toxicity and higher TNFα antagonist therapy 
response rates.
Both TPMT and NUDT15 encode enzymes involved in thiopurine 
metabolism and genetic variation in these genes can lead to defi-
cient thiopurine metabolism. Hence, ‘normal’ starting doses are gen-
erally ‘high’ for patients with defective TPMT or NUDT15 alleles.23,27 
Indeed, patients carrying defective TPMT or NUDT15 alleles are at 
increased risk of thiopurine-induced myelosuppression. We could 
not replicate the association between TPMT and myelosuppression 
using a multivariate model, probably due to the relatively small sam-
ple size. However, we believe there is enough evidence to support 
this well-established association.6,23,28 Pharmacogenetic-guided 
dose reduction decreases the risk of myelosuppression in these 
patients without compromising therapeutic efficacy.29,30 Our data 
show the predicted efficacy of pre-treatment pharmacogenetic test-
ing including both TPMT and NUDT15.
Genetic variation in HLA-DQA1-HLA-DRB1 is a determinant of 
thiopurine-induced pancreatitis, although the mechanism for this re-
mains elusive. We used less stringent criteria for pancreatitis, com-
pared to previous studies, by including suspected cases for whom 
no biochemical or radiological evidence was obtained. Nevertheless, 
by doing so, the incidence of pancreatitis in our cohort was simi-
lar to what is reported in literature.7,31 The relatively small sample 
size might explain why we did not replicate the association. Our data 
show that, if patients were screened for genetic variants in TPMT, 
NUDT15 and HLA-DQA1-HLA-DRB1, 39 patients would need to be 
genotyped to prevent one case of thiopurine toxicity.
It is only recently that HLA-DQA1*05 has been associated with 
an increased risk of immunogenicity of TNFα antagonists in which 
the formation of antibodies targeting the TNFα antagonists leads to 
treatment failure or adverse drug reactions. Although concomitant 
use of immunomodulators can reduce the risk of immunogenicity, 
there are concerns about the safety of this combination therapy. 
Pre-treatment HLA-DQA1*05 genetic testing can identify patients at 
increased risk of immunogenicity and may aid targeted use of com-
bination therapy. Our data show that 32 patients would need to be 
genotyped prior to starting TNFα antagonist treatment to prevent 
one patient from developing immunogenicity.
Currently, American Gastroenterology Association and British 
Society of Gastroenterology guidelines recommend TPMT testing 
prior to thiopurine therapy in addition to regular hematologic moni-
toring, while the European Crohn´s and Colitis Organisation guidelines 
do not recommend any pre-treatment testing.32-34 Pharmacogenetic 
testing prior to TNFα antagonist therapy has not been implemented 
in routine clinical practice. Insufficient evidence to support clinical ef-
ficacy and lack of specialised training for interpretation of complex 
pharmacogenetic data have so far prevented pharmacogenetic testing 
from being widely implemented into clinical care. To our knowledge, 
this study is the first to combine multiple IBD gene-drug interactions 
into clinical efficacy estimates. Combining clinical efficacy estimates 
of thiopurine toxicity and immunogenicity of TNFα antagonists into 
an overall predicted efficacy, we show that 24 patients need to be 
genotyped to prevent one of these adverse drug responses.
Our proposed thiopurine dosing strategies based on TPMT and 
NUDT15 genotypes are in line with guidelines proposed by the Clinical 
Pharmacogenetics Implementation Consortium.23 Prospective stud-
ies are needed to explore the optimal treatment strategy based on 
both HLA genetic variants, which will be a trade-off between the ac-
ceptable risk of adverse reactions and a more timely and systematic 
progression to other (expensive) IBD therapies. Our proposed algo-
rithm excludes patients homozygous at HLA-DQA1-HLA-DRB1 from 
using thiopurines, while allowing patients heterozygous at this locus 
to be exposed to thiopurines. This proposed algorithm is based on the 
high risk (~17%) of pancreatitis in homozygotes,8 the wide availability 
of alternative drugs and the relatively low frequency of homozygotes 
(7%). In contrast, drug avoidance in patients heterozygous at HLA-
DQA1-HLA-DRB1 (~9% risk of pancreatitis) would mean that more 
than one third of patients would be excluded from thiopurine use.
Pre-treatment pharmacogenetic testing can maximise patient 
benefit and minimise harm. Moreover, pharmacogenetic testing has 
the potential to significantly reduce costs associated with IBD treat-
ment, mainly by reducing costs associated with TNFα antagonist 
treatment failure and on hospitalisation for adverse drug reactions.11 
Approximately 30% of the patients experiencing thiopurine-induced 
myelosuppression ultimately require hospitalisation.4 This hospital-
isation is associated with an estimated cost of $5,800 per patient.4,11 
Hospitalisation is necessary for 57% of the patients with thiopu-
rine-induced pancreatitis, with an estimate cost of $33,740 per hos-
pitalisation per patient.35,36 We estimate the costs of a genome-wide 
genotyping array, designed to specifically tag pharmacogenetic pre-
dictors, to be approximately $50 per individual. Based on an overall 
“number needed to genotype” of 24, the costs to prevent one ad-
verse drug reaction will be $1,200. Given these numbers, an IBD 
pharmacogenetic passport should be considered as cost effective to 
optimise IBD treatment.
We used a combination of whole-exome sequencing and a ge-
nome-wide genotyping array to reliably identify genetic variation 
in TPMT, NUDT15 and HLA. With falling costs and wider availabil-
ity of genotyping, future studies should explore which is the most 
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cost-effective genotyping platform that is also easy to implement in 
routine medical care. Furthermore, clinical efficacy estimates pre-
sented in this study are calculated using retrospective case-control 
analyses, while randomised controlled trials are still considered the 
gold standard for clinical efficacy studies. However, randomised con-
trolled trials often fail to produce actionable results, since outcomes 
are averaged across the entire population per study arm, whereas in 
personalised medicine, treatment is based on the individual patient. 
Retrospective studies like this present study should be used as a start-
ing point for prospective studies evaluating clinically implemented 
pharmacogenetic testing.
In conclusion, this is the first study to describe the consequences 
of pre-treatment pharmacogenetic testing for multiple gene-
drug interactions using a real-world IBD cohort. We illustrate that 
pre-treatment pharmacogenetic testing can optimise patient benefit 
and minimise harm. These findings show the predicted efficacy of 
pharmacogenetic testing prior to start of thiopurine or TNFα antag-
onist therapy in patients with IBD.
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